Liraglutide, also a GLP-1 receptor agonist, prevented the accumulation of Aβ plaques, decreased tau hyperphosphorylation and neurofilament proteins, prevented the loss of brain IR and synapses, and reversed cognitive and memory impairment in several mouse models of AD-like pathology and in a non-human primate model of AD [275,276,277]. This evidence concerns the gene GLP1R and Alzheimer disease.